Wk2 Diabetes Clinical Flashcards

1
Q

Alpha cells role in:

1 Blood glucose levels?

  1. glucagon?
  2. liver and kidney?
A
  1. elevate blood glucose
  2. secrete glucagon
  3. liver–secrete glucose kidney– retain glucose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How to differentiate between injected and endogenous insulin:

A

C-peptide levels

**if C-peptide present= endogenous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Autoimmune B-cell destruction:

A

DM1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Progressive insulin secretory defect with insulin resistance:

A

DM2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

antibodies to GAD-65?

A

DM1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Big cause of drug induced hyperglycemia:

A

glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Diagnosed by glucose tolerance test?

A

gestational diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Re-read screening guidelines….

A

slide 26-27

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does Hgb A1c work?

A

measures % of glycosylation on RBC’s

recheck every 3 months (RBC life-span)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diagnostic criteria for diabetes (4):

A
  1. fasting glucose of 126 on two separate occasions
  2. random plasma glucose of 200 with sx (polyuria, polydipsia, weight loss)
  3. A1c > 6.4%
  4. (if pregnant) plasma glucose > 200 two hours after 75g oral glucose bolus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

A1c range for pre-diabetes?

A

5.7-6.4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PE findings in diabetes:

A
  1. BMI – >25 is RF
  2. BP > 140
  3. HEENT – retinal exam (microangiopathic hemorrhage)
  4. Neck – thyroid – possible MEN syndrome
  5. CV/Lungs: weak pulses, carotid bruits
  6. skin: ulcers, brown pigment
  7. reflexes and sensation: monofilament test
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Microvascular complications of DM:

A

retinopathy

neuropathy

nephropathy (microalbumin screening)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Macrovascular complications of DM:

A

atherosclerosis (should be on aspirin px)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Labs to check in DM: (7)

A

glucose

A1c

lipids

microalbumin (urine??)

TSH

liver panel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BP goal in DM management:

A

140/80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LDL goal in DM management:

A

100 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

First line therapy for mild DM:

19
Q

Two drug that can lower A1c the most:

A

Metformin (a biguanide)

Sulfonylureas

  • glyburide
  • glipizide
  • glimipiride

**can lower 1-2%

20
Q

Two drug classes that increases satiety:

A

amylin analogs (Pramlintide)

GLP-1 agonists (Exenatide, Liraglutide)

21
Q

Drug class that decreases glucose absorption in the gut:

A

Alpha-glucosidase inhibitors (acarbose, miglitol)

22
Q

Three drug classes that decrease gastric emptying:

A

GLP-1 agonists —- Exenatide, Liraglutide

DPP-IV inhibitors —- “–gliptins”

amylin analogs —- Pramlintide

23
Q

Two drugs that decrease glucose production:

A

Metformin

TZDs —- Pioglitazone, Posiglitizone

24
Q

4 drugs that increase insulin secretion:

A
  1. sulfonylureas – Glimepiride, Glipizide, Glyburide
  2. GLP-1 agonists — Exenatide, Liraglutide
  3. DDP-IV inhibitors — “–gliptins”
  4. Meglitinides
25
3 drugs that decrease glucagon secretion:
1. GLP-1 agonists --- Exenatide, Liraglutide 2. DPP-IV inhibitors --- "--gliptins" 3. Amylin analogs --- Pramlintide
26
Two drugs that increase peripheral glucose uptake:
Metformin TZDs --- Pioglitazone, Rosiglitazone
27
Drug that decreases glucose reabsorption:
SGLT2 inhibitors --- Canagliflozin
28
Contraindications for Metformin:
renal impairment cardiac/respiratory deficiency sepsis lactic acidosis liver disease/EtOH abuse **radiographic contrast
29
Creatinine cutoff for Metformin:
males: > 1.5 females: >1.4
30
Patient case...
slide 50
31
MOA of sulfonylureas:
bind sulfonylurea receptor on beta cells --> stimulate insulin release
32
side fx of sulfonylureas:
hypoglycemia weight gain potential cardiac probs
33
MOA of TZDs:
increase glucose uptake in muscle keeps liver from overproducing glucose
34
side fx of TZD's:
edema*** CHF?? MI?? $$$$$
35
MOA of GLP-1 agonists:
increased glucose dependent insulin secretion decrease glucagon secretion delay gastric emptying $$$$$
36
MOA of DPP-IV inhibitors:
prevents degradation of GLP-1 and GIP $$$$
37
Contraindication of GLP-1's:
Thyroid cancer
38
Short acting insulins:
Rapid** - Aspart - Lispro - Glulisine Short** Regular
39
Long acting insulins (for establishing basal levels):
NPH ----- intermediate Detemir ----- long 6-24 hrs Glargine (Lantus)------ long > 24 hrs
40
A1c target for most patients:
41
When is A1c target 6-6.5%?
short disease duration long life expectancy no CVD
42
When is A1c goal 7.5-8%?
h/o severe hypoglycemia short life expectancy comorbidities and complications difficult control
43
Only medical therapy without a ceiling?
insulin
44
When can oral therapy be dc'd?
start of insulin